ZEALAND PHARMA/S (NASDAQ:ZEAL) and iCo Therapeutics (OTCMKTS:ICOTF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings & Valuation

This table compares ZEALAND PHARMA/S and iCo Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ZEALAND PHARMA/S $6.02 million 119.87 $92.07 million $3.00 7.81
iCo Therapeutics N/A N/A -$1.30 million N/A N/A

ZEALAND PHARMA/S has higher revenue and earnings than iCo Therapeutics.

Profitability

This table compares ZEALAND PHARMA/S and iCo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ZEALAND PHARMA/S N/A 50.63% 41.41%
iCo Therapeutics N/A N/A -296.49%

Analyst Ratings

This is a breakdown of recent ratings for ZEALAND PHARMA/S and iCo Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZEALAND PHARMA/S 1 2 2.67
iCo Therapeutics N/A

ZEALAND PHARMA/S currently has a consensus price target of $31.00, suggesting a potential upside of 32.25%. Given ZEALAND PHARMA/S’s higher possible upside, research analysts plainly believe ZEALAND PHARMA/S is more favorable than iCo Therapeutics.

Insider and Institutional Ownership

9.4% of ZEALAND PHARMA/S shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

ZEALAND PHARMA/S has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, iCo Therapeutics has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500.

Summary

ZEALAND PHARMA/S beats iCo Therapeutics on 7 of the 8 factors compared between the two stocks.

ZEALAND PHARMA/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company’s product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH; and Alexion Pharmaceuticals, Inc. for the discovery and development of peptide therapies for complement-mediated diseases. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

iCo Therapeutics Company Profile

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.

Receive News & Ratings for ZEALAND PHARMA/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com’s FREE daily email newsletter.



READ SOURCE

READ  Two-Thirds of Small Cap ICO Tokens Losing Value

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here